CURRICULUM VITAE

NAME	Minkyu Jung, M.D., Ph.D.
ADDRESS	Yonsei University College of Medicine
	50-1 Yonseiro, Seodaemun-gu, Seoul, 03722, Korea
POSITION	Associate Professor
	Division of Medical Oncology, Department of Internal Medicine
	Yonsei cancer center, Yonsei University Healthy System
PHONE	82-2-2228-8128 (Office)
	82-10-2648-2846 (Cell phone)
FAX	82-2-393-3652
E-Mail	minkjung@yuhs.ac
CITIZENSHIP	KOREAN

Licenses and Qualifications

2003 Doctor of Medicine and License of General Medicine (#79100) – Korea

2009 Board of Internal Medicine (#11892) – Korea

2011 Subspecialty in Hematology/Oncology (#611413) – Korea

Education Background & Professional Experience

Academic background

1995-1999 Department of Biology
Yonsei University College of Science
Seoul, Korea

1999-2003 Yonsei University College of Medicine
Seoul, Korea

2006-2008 Master of Medical Science, Graduate School
Yonsei University College of Medicine, Seoul, Korea

Thesis: "The clinical usefulness of ascitic fluid CEA in advanced gastric cancer patients with ascites"

2008-2017 Doctor of Philosophy, Medical Science, Graduate School
Yonsei University College of Medicine, Seoul, Korea
Thesis: "Inhibition of CK2 to overcome paclitaxel resistance in gastric cancer"

Professional experience

2003.3-2004.2 Rotating Internship
Yonsei University College of Medicine
Yonsei Medical Center, Severance Hospital
Seoul, Korea

2005.3-2009.2 Residency in Internal Medicine
Yonsei University College of Medicine
Yonsei University Health System, Severance Hospital
Seoul, Korea

2009.3-2010.2 Clinical fellow in Medical Oncology
Division of Medical Oncology, Department of Internal Medicine
Yonsei Cancer Center, Yonsei University College of Medicine
Yonsei University Health System,Seoul, Korea

2010.3-2010.9 Assistant Clinical Research Professor in Medical Oncology
Division of Medical Oncology, Department of Internal Medicine
Yonsei Cancer Center, Yonsei University College of Medicine
Yonsei University Health System, Seoul, Korea

2010.10-2011.2 Clinical Instructors in Medical Oncology
Gachon University Gil hospital

2011.3-2012.2 Clinical Assistant Professor in Hematology and Oncology
Gachon University Gil hospital

2012.3-2014.2 Clinical Assistant Professor in Medical Oncology
Yonsei cancer center, Yonsei University Healthy System

2014.3-201.2 Assistant Professor in Medical Oncology
Yonsei cancer center, Yonsei University Healthy System

2019.3-Current Associate Professor in Medical Oncology
Yonsei cancer center, Yonsei University Healthy Syste

Membership

2005 Korean Association of Internal Medicine

2008	Korean Cancer Association
2008	Korean Cancer Study Group
2008	Korean Society of Medical Oncology
2010	American Society of Clinical Oncology
2010	American Association for Cancer Research
2010	European Society of Medical Oncology

Medical Journal Reviewer and Editor

Editor, Yonsei Medical Journal, 2020-

Reviewer, Korean Journal of Medicine, 2014-

Grants as a Principal Investigator

1. Grant of Korea Health Care Technology R & D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea. Jun 2009-Feb 2010. Title: MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer
2. Grant of Korea Health Care Technology R & D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea. Jun 2010-Feb 2011. Title: Osteopontin as a predictive biomarker in gastric cancer treated with capetabine and oxaliplatin
3. Grant of Korean Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning, Mar. 2014-Feb.2017. Title: Study of oncogenic function of novel fusion gene in melanoma
4. Grant of Faculty research Grant in Internal Medicine, Yonsei University College of Medicine Mar. 2014-Feb.2015. Title: The prognostic role of metformin in Gastric Cancer

5. Grant of Faculty research seed money Grant of Yonsei University College of Medicine Mar. 2014-Feb.2015. Title: Prognostic value of FDG-PET CT in patients with gastric neuroendocrine carcinoma.
6. Grant of Faculty research Grant in Internal Medicine, Yonsei University College of Medicine Mar. 2015-Feb.2016. Title: Identification of resistance to c-KIT inhibitor in malignant melanoa haboring c-KT mutation
7. Grant of Faculty research Grant of Yonsei University College of Medicine Mar. 2015-Feb.2016. Title: Evaluation of molecular resistance mechanism of paclitaxel and efficacy of combined therapy paclitaxel with receptor tyrosin kinase inhibitor in gastric cancer
8. Grant of Yonsei University Future-leading Research Initiative of Yonsei University, Mar 2014-Feb.2017, Title: Identification of resistant mechanism of anti-HER2 therapy in gastric cancer using patient derived tumor xenograft model
9. Grant of Faculty research Grant of Yonsei University College of Medicine Sep. 2019-Aug.2020. Tile; Investigation of cancer stem cell targeting agent, TRX-E-002 in gastric cancer
10. Grant of a project to support public clinical trials funded by Korean National Enterprise for Clinical Trial, 2020, Title: An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination with ZW25 as a 2nd line in HER2 Positive Advanced Gastric Cancer
11. Grant of Faculty research Grant of Yonsei University College of Medicine Dec. 2020-Nov.2021, Title: Identification of predictive biomarker for FGFR inhibitors using organoid derived from gastric cancer patients
12. Grant of Cancer Research Support Project by Korean Foundation for Cancer Research, Dec. 2020-Nov. 2021. Title: Development of a personalized national gastric cancer screening program

Invited Lecture

1. May 2017, The 31rd Consensus Conference of Gastric Cancer in Korean Society of Medical Oncology (KSMO) -Patient selection and combination strategy of immunotherapy
2. Nov. 2019, 8th Joint Scientific Meeting of RCR & HKCR and 27th Annual Scientific Meeting of HKCR, Hong Kong- Efficacy and tolerability of ramucirumab monotherapy or in

combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)

3. Nov. 2019, KSMO International Symposium, 2019 -Clinical benefit of ramucirumab as second-line therapy in advanced gastric cancer

4. Dec. 2019, Korean Society of Biological Nursing Science -Immunotherapy in Advanced Gastric Cancer

5. Jan. 2020, KAIRB-Review of Non-Compliance Case

6. Jan. 2020, Celltrion Lecture -Chemotherapy and Immunotherapy in Advanced Gastric Cancer

7. Jun. 2020, Boryung Symposium -Cancer Cachexia and Treatment in Cancer Patients

8. Jul. 2020, 15th Methodology Workshop in Korean Cancer Study Group-Overview of Genomic Biomarker Driven Clinical Trial

9. Aug. 2020, LSK education lecture-Design of Clinical Trial with Targeted Agents

10. Sep. 2020, KSMO International Symposium -Patient-centred treatment strategies for breakthrough cancer pain

11. Oct. 2020 The 43rd Consensus Conference of Gastric Cancer & Sarcoma in KCSG-Emerging new targeted therapy or immunotherapy

12. Nov. 2020, Mundi Pharm Pain Symposium -Optimal Cancer Pain Management

13. Nov. 2020, Opdivo Attraction Symposium, Ono Pharma Korea and Bristol Myers Squibb (BMS) -Evolution of Treatment Strategy & Patient Management in GC Salvage Line

14. May. 2021, Annual Symposium of Korean Society of Medical Oncology 2021-Hyperprogressive disease during immunotherapy with PD-1 blockade or chemotherapy with irinotecan in patients with advanced gastric cancer

Awards

1. 2005 Best Student Award from Yonsei University
2. 2008 Young Investigator Award from Korean Association for Clinical Oncology
3. 2009 Excellent Graduate Student form Korean Cancer Association.

4. 2010 Best Abstract from Korean Association for Clinical Oncology
5. 2011 Award for Excellent oral presentation from Korean Association for Clinical Oncology
6. 2013 Award for Excellent oral presentation from Korean Association for Clinical Oncology
7. 2013 Excellence in Research Award form Merck-Serono and Korean Association for Clinical Oncology
8. 2017 Young Investigator Research Award from Boryung and Korean Association for Clinical Oncology
9. 2020 Excellence in Research Award form Roche and Korean Cancer Association

Advisory Board

1. Norvatis APECHO (Asia-Pacific Educational Centers for Hematology & Oncology) Advisory Board Meeting , 2020
2. Green Cross Cell, since 2020

Publications

1. Byun HK, Chang JS**, Jung M**, Koom WS, Chung KY, Oh BH, Roh MR, Kim KH, Lee CK, Shin SJ. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. Front Oncol. 2021 May 27;11:659754
2. Song JH, Lee S, Choi S, Cho M, Kwon IG, Kim YM, Son T, Kim HI, **Jung M**, Hyung WJ. Adverse Prognostic Impact of Postoperative Complications After Gastrectomy for Patients With Stage II/III Gastric Cancer: Analysis of Prospectively Collected Real-World Data. Front Oncol. 2021 Apr 29;11:611510.
3. Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, **Jung M**, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021 Jun;594(7863):418-423

4. Han JW, Heo W, Lee D, Kang C, Kim HY, Jun I, So I, Hur H, Lee MG, **Jung M**, Kim JY. Plasma Membrane Localized GCaMP-MS4A12 by Orai1 Co-Expression Shows Thapsigargin- and Ca2+-Dependent Fluorescence Increases. Mol Cells. 2021 Apr 30;44(4):223-232. ***Co-Corresponding author***

5. Park JS, Choe EA, Park S, Nam CM, Hyung WJ, Noh SH, Lee S, Kim HS, **Jung M**, Chung HC, Rha SY. Detection of asymptomatic recurrence improves survival of gastric cancer patients. Cancer Med. 2021 May;10(10):3249-3260.

6. Lee JB, **Jung M**, Beom SH, Kim GM, Kim HR, Choi HJ, Sohn JH, Ahn JB, Rha SY, Chung HC. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Invest New Drugs. 2021 Mar 15.

7. Lee JB, **Jung M**, Kim JH, Kim BH, Kim Y, Kim YS, Kim BC, Kim J, Moon SH, Park KU, Park M, Park HJ, Sim SH, Yoon HM, Lee SJ, Lee E, Chun JY, Chung YK, Jung SY, Chung J, Lee ES, Chung HC, Yun T, Rha SY. Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. ancer Res Treat. 2021 Apr;53(2):323-329. - ***Co-1st author***

8. Hwang SH, **Jung M**, Jeong YH, Jo K, Kim S, Wang J, Cho A. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors.

9. **Jung M,** Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, Jin MM.Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Mol Ther Oncolytics. 2020 Aug 21;18:587-601

10. Park H, **Jung M,** Kim MJ, Min J, Lee CK, Shin SJ, Beom SH, Ahn JB, Jeon JY. Objectively Measured Physical Activity During Chemotherapy in Colon Cancer Patients. Support Care Cancer. 2020 Jun;28(6):2597-2604. doi: 10.1007/s00520-019-05049-9. Epub 2019 Oct 14. -***Co-1st author***

11. **Jung M**, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Efficacy and tolerability of ramucirumab

monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print] - ***Co-1st author***

12. Lee CK, **Jung M**, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2018 Feb 5. doi: 10.4143/crt.2018.028. [Epub ahead of print]-***Co-1st author***

13. Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, **Jung M**, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer. 2018 Jan 25. doi: 10.1007/s10120-018-0794-1. [Epub ahead of print]

14. Kim JH, Shin SJ, Heo SJ, Choe EA, Kim CG, Jung M, Keum KC, Yoon JS, Lee SC, Shin SJ. Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. Cancer Res Treat. 2017 Dec 28. doi: 10.4143/crt.2017.534. [Epub ahead of print]

15. Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T, Kim HI, Cheong JH, Hyung WJ, Choi SH, **Jung M**, Kim HS, Jeung HC, Chung HC, Rha SY, Noh SH. Multidisciplinary Treatment for Patients With Stage IV Gastric Cancer: The Role of Conversion Surgery Following Chemotherapy. BMC Cancer. 2018 Nov 15;18(1):1116. doi: 10.1186/s12885-018-4998-x.

16. Park HS, Kim HS, Beom SH, Rha SY, Chung HC, Kim JH, Chun YJ, Lee SW, Choe EA, Heo SJ, Noh SH, Hyung WJ, Cheong JH, Kim HI, Son T, Lim JS, Baek SE, **Jung M.** Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study From the CLASSIC Trial. Ann Surg Oncol. 2018 Oct;25(11):3222-3230. doi: 10.1245/s10434-018-6624-1. Epub 2018 Jul 26-***Corresponding author***

17. Park HS, Lee JB, **Jung M.** ASO Author Reflections: Prognostic Impact of Body Composition Change After Gastrectomy for Advanced Gastric Cancer. Ann Surg Oncol.

2018 Dec;25(Suppl 3):765-766. doi: 10.1245/s10434-018-7017-1. Epub 2018 Nov 12. -***Corresponding author***

18. Kim C, Kim WR, Kim KY, Chon HJ, Beom SH, Kim H, Jung M, Shin SJ, Kim NK, Ahn JB. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection, Clin Colorectal Cancer. 2018 Sep;17(3):e513-e518. doi: 10.1016/j.clcc.2018.03.011. Epub 2018 Mar 29

19. Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, **Jung M,** Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC). Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

20. Ji Soo Park, Jong-Chan Youn, Chi Young Shim, Geu-Ru Hong, Choong-Kun Lee, Jee Hyung Kim, Hyung Soon Park, Su Jin Heo, Seung Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Seok-Min Kang, and **Minkyu Jung.** Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget. 2017; 8:61837-61845-***Corresponding author***

21. Kim CG, Ahn JB, Shin SJ, Beom SH, Heo SJ, Park HS, Kim JH, Choe EA, Koom WS, Hur H, Min BS, Kim NK, Kim H, Kim C, Jung I, **Jung M**. Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. BMC Cancer. 2017 Sep 2;17(1):615-***Corresponding author***

22. Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, **Jung M**. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2017 Jun 22. doi: 10.1007/s10120-017-0739-0. [Epub ahead of print] -***Corresponding author***

23. Kim HS, Lee H, Shin SJ, Beom SH, **Jung M**, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS7, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to

select targeted therapy for advanced gastric cancer. Oncotarget. 2017 Jun 13;8(24):38389-38398.

24. Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, **Jung M**. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget. 2017 May 9;8(19):31169-31179-***Corresponding author***

25. HS Kim, **M Jung**, HN Kang, H Kim, C-W Park, S-M Kim, SJ Shin, SH Kim, SG Kim, EK Kim, MR Yun, Z Zheng, KY Chung, J Greenbowe, SM Ali, T-M Kim and BC Cho. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene. 2017 Jan 16. Epub. –***Co-1st author***

26. Kim CG, Ahn JB, **Jung M**, Beom SH, Heo SJ, Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, Kim H, Roh YH, Ma BG, Shin SJ. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Ann Surg Oncol. 2017 Jan;24(1):227-235.

27. Yoon HI, Koom WS, Kim TH, Ahn JB, **Jung M**, Kim TI, Kim H, Shin SJ, Kim NK. Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. PLoS One. 2016 Aug 18;11(8):e0161475.

28. Kim HS, Shin SJ, Beom SH, **Jung M**, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget. 2016 Jul 12;7(28):44608-44620.

29. Kim CG, Ahn JB, **Jung M**, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016 Jun 28;115(1):25-33

30. **Jung M**, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, Lee SJ, Shin SJ. Ipilimumab Real-world Efficacy and Safety in Korean melanoma Patients from the Korean Named-Patient Program Cohort. Cancer Res Treat. 2017 Jan;49(1):44-53. -***Co-1st author***

31. Lim SM, Cho BC, Kim SW, Kang SY, Heo DS, Kim HT, Lee DH, Kim DW, **Jung M**, Choi JH, Shim HS, Choi JR, Kim JH. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer. 2016 Mar;93:1-8.

32. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, **Jung M**. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Ann Nucl Med. 2016 May;30(4):279-86. -***Corresponding author***

33. Kim KH, Shin SJ, Cho MS, Ahn JB, **Jung M**, Kim TI, Park YS, Kim H, Kim NK, Koom WS. A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiother Oncol. 2015 Dec 16. pii: S0167-8140(15)00649-0. doi: 10.1016/j.radonc.2015.11.029. [Epub ahead of print]

34. **Jung M**, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, Min BS, Baik SH, Kim NK, Kim H, Lim JS, Hong SP, Kim TI, Roh JK, Park YS, Ahn JB. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1015-22.

35. Park HS, **Jung M**, Shin SJ, Heo SJ, Kim CG, Lee MG, Beom SH, Lee CY, Lee JG, Kim DJ, Ahn JB. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. Ann Surg Oncol. 2015 Oct 29. [Epub ahead of print] -***Corresponding author***

36. Lee CK, **Jung M**, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients who Failed First-line Therapy Containing Darcabazine. Cancer Res Treat. 2015 Feb 16. doi: 10.4143/crt.2014.261. [Epub ahead of print]

37. Heo SJ, Lee CK, Hahn KY, Kim G, Hur H, Choi SH, Han KS, Cho A, **Jung M**. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas. Cancer Res Treat. 2015 Feb 17. doi: 10.4143/crt.2014.299. [Epub ahead of print] -***Corresponding author***

38. Lee CK, **Jung M**, Jung I, Heo SJ, Jeong YH, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS, Rha SY, Chung HC. Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. Ann Surg. 2015 Jan 8. [Epub ahead of print]-***Corresponding author***

39. Lim SM, **Jung M**, Shin SJ, Baek SJ, Hur H, Min BS, Baik SH, Kim NK, Ahn JB. Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients. Oncology. 2014 Dec 5;88(4):195-200. [Epub ahead of print]

40. Park JS, Rha SY, Chung HC, **Jung M**, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. Oncology. 2014 Nov 13;88(3):147-156. [Epub ahead of print]

41. Zhang X, Park JS, Park KH, Kim KH, **Jung M**, Chung HC, Rha SY, Kim HS.PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. Oncology. 2015;88(2):76-85

42. Park HS, **Jung M**, Kim HS, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, Rha SY. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Ann Surg Oncol. 2015 Jan;22(1):224-31- ***Co-1st author***

43. Ahn HK, **Jung M**, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Jun 7.

44. Ahn HK, **Jung M**, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumour Biol. 2014 Jun;35(6):5735-40- ***Co-1st author***

45. Yi JH, Kim H, **Jung M**, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia. Oncology. 2013;85(5):283-9

46. **Jung M**, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Cho BC. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J. 2013 Jul;54(4):854-64

47. **Jung M**, Choi EH, Nam CM, Rha SY, Jeung HC, Lee SH, Yang WI, Roh JK, Chung HC. Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. Ann Surg Oncol. 2013 Aug;20(8):2615-24.

48. **Jung M**, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012 Nov 1;53(6):1128-35

49. **Jung M**, Kim GW, Jung I, Ahn JB, Roh JK, Rha SY, Chung HC, Kim NK, Kim TI, Shin SJ. Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. BMC Cancer. 2012 Oct 12;12:471

50. **Jung M**, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS One. 2012;7(9):e45127. doi: 10.1371/journal.pone.0045127. Epub 2012 Sep 20

51. Sym SJ, Hong J, **Jung M**, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2012 Aug;70(2):277-84. Epub 2012 Jun 30.

52. Noh S, Jung JJ, **Jung M**, Kim KH, Lee HY, Wang B, Cho J, Kim TS, Jeung HC, Rha SY. Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Oncol Lett. 2012 Mar;3(3):699-703. Epub 2012 Jan 3.

53. Noh S, Jung JJ, **Jung M**, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, Rha SY. MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer.

Hepatogastroenterology. 2011 Oct 12;58(112). doi: 10.5754/hge11209. [Epub ahead of print]

54. Hong J, Park S, Park J, Kim HS, Kim KH, Ahn JY, Rim MY, **Jung M**, Sym SJ, Cho EK, Shin DB, Lee JH. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 2011 Oct;52(10):1904-12. Epub 2011 Jun 30.

55. **Jung M**, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, Chang J, Rha SY, Kim JH, Kim DJ, Cho BC. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med. 2011 Jul;2(4):685-693

56. Hong J, **Jung M**, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol. 2011 Jun 21. [Epub ahead of print]

57. Hong S, Shin SJ, **Jung M**, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY. Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. Oncology. 2011 Jun 14;80(1-2):107-117. [Epub ahead of print]

58. Shin SJ, **Jung M**, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs. 2011 May 13. [Epub ahead of print]

59. Hong S, Cho BC, Choi HJ, **Jung M**, Lee SH, Park KS, Kim SK, Kim JH. Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients.Oncology. 2011 Mar 16;79(3-4):293-300. [Epub ahead of print]

60. **Jung M**, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, Rha SY. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011 Jan;101(1):49-55. Epub 2010 May 14. J Neurooncol. 2010 May 14.

61. **Jung M**, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. The clinical outcome of chemotherapy induced amenorrhea in premenopausal young breast cancer patients with long term follow up. Ann Surg Oncol. 2010 Dec;17(12):3259-3268. Epub 2010 Jun 19.

62. **Jung M**, Jeung HC, Lee SS, Park JY, Hong S, Lee SH, Noh SH, Chung HC, Rha SY. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol. 2010 Apr;136(4):517-26. Epub 2009 Sep 23.

63. Jung JJ, Noh S, Jeung HC, **Jung M**, Kim TS, Noh SH, Roh JK, Chung HC, Rha SY. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Cancer Sci. 2010 Oct;101(10):2200-6. doi: 10.1111/j.1349-7006.2010.01666.x. Epub 2010 Aug 22

64. Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, **Jung MK**, Shin SJ, Park MS, Kim SK, Chang J, Kim JH. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer. 2010 Oct;70(1):77-81. Epub 2010 Mar 16.

65. Son JW, Kim JS, Lee JM, Hong SJ, **Jung MK**, Kim DH, Kim JS, Choi D, Jang Y. Percutaneous cardiopulmonary support in refractory no-reflow with cardiogenic shock after coronary stenting in acute myocardial infarction. Yonsei Med J. 2010 Jul;51(4):599-601.

66. Moon YW, Sohn JH, Kim YT, Chang H, Jeong JH, Lee YJ, Chang J, Kim SK, **Jung M**, Hong S, Choi SH, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer. Anticancer Res. 2009 Oct;29(10):4243-9.

67. Ahn JR, **Jung M**, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Prognosis of pN3 Stage Gastric Cancer. Cancer Res Treat. 2009 Jun;41(2):73-9. Epub 2009 Jun 30

68. Kim DH, Cheon JH, Moon CM, Park JJ, Han SY, Kim ES, Chung MJ, Lee JH, **Jung MK**, Lee SH, Son JW, Kim TI, Kim WH. Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess. Korean J Gastroenterol. 2009 Jan;53(1):29-35.

69. **Jung MK**, Hong SJ, Lee SH, Hong SJ, Son JW, Kang W, Lee YW, Hong CS, Lee JK, Park JW. Development and Validation of a Korean Allergic Rhinitis-specific Quality of Life Questionnaire (KARQLQ). Korean J Asthma Allergy Clin Immunol 2008;28:113-120